New hope for Hard-to-Treat breast cancer? alisertib combo tested
NCT ID NCT02860000
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tested the drug alisertib, alone or combined with fulvestrant, in 96 postmenopausal women with advanced breast cancer that no longer responds to hormone therapy. Alisertib blocks enzymes that help cancer cells grow, while fulvestrant blocks estrogen. The goal was to see if these treatments could shrink tumors. The study is complete, but results are not yet widely available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- alisertib and fulvestrant
- What this could lead to
- If successful, this could offer a new treatment option for women with advanced breast cancer that no longer responds to standard hormone therapy.
- What could go wrong
- This is a small, early-phase trial (96 participants) with no guarantee of success. The combination may not improve outcomes or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOCRINE-RESISTANT BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Georgetown University Medical Center
Washington D.C., District of Columbia, 20007, United States
-
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Montefiore Medical Center
The Bronx, New York, 10461, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
-
Vanderbilt Breast Center at One Hundred Oaks
Nashville, Tennessee, 37204, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Fasting during chemo: a new way to boost treatment?
- Can a Two-Drug attack shrink Hard-to-Treat breast cancer?
- Can mapping tumor DNA unlock personalized breast cancer care?
- Can a drug cocktail cure metastatic breast cancer? a trial aims to find out
- Could a personal coach at home boost energy for cancer patients?
- Does menopause change the 'Love Hormone'? a study investigates